Description | Cabergolineisanergotderived-dopamineD2-likereceptoragonistthathashighaffinityforD2,D3,and5-HT2Breceptors(Ki=0.7,1.5,and1.2,respectively). |
---|---|
IC50&Target | Ki:0.7(DopamineD2receptor),1.5(DopamineD3receptor),1.2(5-HT2Breceptor)[1] |
InVitro | CabergolineactsasapotentagonistofD2,D3and5-HT2Breceptors.PretreatmentwithCabergolineinhibitsH2O2-inducedneuronalcelldeathinadose-dependentmanner.Inthefollowingexperiments,10µMofCabergolineisusedtoinvestigateitsneuroprotectiveeffects.MAP2stainingrevealsthatCabergolinesignificantlysuppressesthelossofneuronscausedbyH2O2incubation.ThedetectionofapoptoticnuclearcondensationsuggestedthatCabergolinepreventsapoptoticcelldeathfollowingH2O2exposure[1]. |
InVivo | Cabergolinehasalongereliminationhalf-life(63to109h)comparedwithotherD2-likereceptoragonists,bothalong-lastingclinicaleffectfollowingsingle-doseadministration,andanimprovementinthequalityoflifeofpatientswithchronicdiseasesareexpected[1].Themostsignificantreductioninrapideyemovement(REM)sleepboutnumberoccurredduringthelightphase,inwhichCabergoline-injectedfemalehandledmicehas67.3%lessREMsleepbouts(F(1,11)=12.892,P=0.004)thanCabergoline-injectedfemalesthatarerestrained,althoughthegreatestnumberinreductionofREMsleepboutsoccurrduringthedarkphase(82.3%fewerREMsleepbouts;F(1,11)=3.667,P=0.082).Inmalemice,CabergolinereducesbaselineProlactin(PRL)levels(98.5%;F(1,6)=13.192,P=0.011)from5.8±1.3to0.08ng/mLwithin2hoursofinjection.Aftera7-dayrecoveryperiod,PRLlevelsreturntovaluesthatarenotdifferentfrombaseline(5.0±0.60ng/mL;F(1,6)=0.715,P=0.43)[2]. |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CellAssay [1] | CabergolineisdissolvedinDMSOandstored,andthendilutedwithappropriatemediumbeforeuse[1]. Primarycorticalneuronsareprepared.Cabergoline(10µM;exceptforexperimentsofdose-dependency)isappliedtocorticalcellsatDIV6-7.After24-hourCabergolinetreatment(exceptforexaminationofpretreatmenttime-dependencyofCabergoline),H2O2(50µM;exceptforthedose-dependencyofH2O2)isadded.Allinhibitorsandantagonists,includingspiperone,U0126,SB203580,SP600125,AP5,andnifedipineareapplied20minbeforeCabergolineorH2O2addition.L-glutamateisaddedatDIV7-8forcelldeathinduction.CellsurvivalrateismeasuredbyMTTassay.Aftertheindicatedtreatmentwithdrugsiscompleted,culturemediumisreplacedwith200µLfreshmediumcontaining40µlMTTsolution(2.5mg/mL,dilutedinPBS)andcellsareincubatedat37°Cfor1.5-2.5hours.Then,200µLlysisbuffercontainingisopropylalcoholisappliedtoeachwellandmixedbypipetting.Eachsampleismovedtoa96-wellplateanditsabsorbanceat570nmismeasuredusinganiMarkMicroplateleader.Cellsurvivalrateisquantitatedbyabsorbancemeasurement,becauseMTT(yellow)isdeoxidizedtoformazan(violet)inproportiontomitochondrialactivity[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
AnimalAdministration [2] | Cabergolineisdissolvedin100%pharmasolveandthendilutedwith20%β-cyclodextrininwatertoyieldafinalconcentrationof0.15-0.5mg/mL[2]. Mice[2] | ||||||||||||||||
References |
|
MolecularWeight | 451.6 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula | C₂₆H₃₇N₅O₂ | ||||||||||||
CASNo. | 81409-90-7 | ||||||||||||
Storage |
| ||||||||||||
Shipping | RoomtemperatureincontinentalUS;mayvaryelsewhere | ||||||||||||
Solvent&Solubility | DMSO:≥33mg/mL *"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> Purity:99.47% 品牌介绍
托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-Tropanylindole-3-carboxylate;lαH,5Αh-Tropan-3α-ylindole-3-carboxylate中文名称:托烷司琼中文同义词:托普西隆;托普西龙;曲匹西龙;托烷司琼;Β-托烷司琼;CS-348;Β-内托烷司琼;吲哚-3-甲酰氯;Β-托烷司琼(光学异构体);Β-托烷司琼,托烷司琼异构体CBNumber:CB3236404分子式:C17H20N2O2分子量:284.35MOLFile:89565-68-4.mol化学性质安全信息用途供应商112化学性质安全信息用途供应商112托烷司琼化学性质熔点:201-202°C沸点:448.5±35.0°C(Predicted)密度:1.26储存条件:2-8°C溶解度:H2O:soluble形态:solid酸度系数(pKa):15.38±0.30(Predicted)颜色:whiteCAS数据库:Chemicalbook89565-68-4(CASDataBaseReference)安全信息WGKGermany:3托烷司琼化学药品说明书托烷司琼|药物应用信息托烷司琼性质、用途与生产工艺临床评价Sorbe等报道本品对含顺铂(剂量50~89mg/m2)化疗方案引起的急性呕吐完全控制率为63%。58例恶性肿瘤化疗所致恶心、呕吐者,应用托烷司琼或昂丹司琼8mg分别在同一病人前后2个化疗周期的第1d给药前30min静脉注射,并用地塞米松10mg静脉滴注。结果两药控制急性及迟发性恶心、呕吐的疗效基本相似,均可达81%~100%。本品对强致吐化疗药物顺铂的止吐疗效突出。药物相关作用饮食可略为延长本品的吸收。本品与利福平、苯巴比妥等肝酶诱导药同时使用,可加快代谢,故快代谢型者需增加剂量,慢者则不必。西咪替丁等肝酶抑制药对本品血药浓度无明显影响。适应症托烷司琼临床用于预防和治疗癌症化疗引起的恶心和呕吐。化学性质结晶,熔点201-202℃(二氯甲烷-乙酸乙酯)。单盐酸托烷司琼(TropisetronMonohydroehloride):C17H20N2O2?HCI。[105826-92-4]。熔点283-285℃(分解)。用途有高效性和选择性的5-HT3受体拮抗剂。用于化疗所致的呕吐。用途为5-羟色胺拮抗药生产方法托品醇(I)和酰氯(Ⅱ)反应,可得托烷司琼。托烷司琼上下游产品信息上游原料托品醇下游产品
联络我们
|